| P50 | author | Gergely Feher | Q59187533 |
| | László Czopf | Q96089627 |
| P2093 | author name string | Elod Papp | |
| | Kalman Toth | |
| | Gabor Kesmarky | |
| | Katalin Koltai | |
| | Peter Kenyeres | |
| | Laszlo Czopf | |
| | Alexander Solyom | |
| | Balint Alkonyi | |
| P2860 | cites work | Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 |
| | Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel | Q28165762 |
| | Aspirin resistance | Q28167475 |
| | Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment | Q28167868 |
| | Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation? | Q28174175 |
| | Platelet-active drugs : the relationships among dose, effectiveness, and side effects | Q28175147 |
| | Profile and prevalence of aspirin resistance in patients with cardiovascular disease | Q28186905 |
| | Cyclooxygenase inhibitors and the antiplatelet effects of aspirin | Q28191912 |
| | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events | Q28192726 |
| | Aspirin non-responder status in patients with recurrent cerebral ischemic attacks | Q28194630 |
| | A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease | Q28195458 |
| | Aspirin resistance: a new independent predictor of vascular events? | Q28195460 |
| | Aspirin resistance: definition, mechanisms and clinical read-outs | Q28199030 |
| | Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial | Q28199508 |
| | Aspirin resistance in stroke: 2004 | Q28210075 |
| | A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial | Q28210362 |
| | Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction | Q34168972 |
| | Mechanisms for antiplatelet action of statins | Q36107673 |
| | Inhibition of polymer-induced red blood cell aggregation by poloxamer 188. | Q40731161 |
| | A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study | Q40818460 |
| | Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) | Q40906958 |
| | Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy | Q43562633 |
| | Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. | Q43812103 |
| | Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies | Q43950275 |
| | Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study | Q44604925 |
| | Carvedilol--a beta-blocker with considerable antiaggregatory effect on human blood platelets. | Q46470132 |
| | Hematocrit and the risk of coronary heart disease: the Honolulu Heart Program. | Q52706900 |
| | Development of aspirin resistance in persons with previous ischemic stroke. | Q54189504 |
| | Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease | Q56944813 |
| | Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease: The Caerphilly and Speedwell Studies | Q60687352 |
| | Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study | Q68979773 |
| | Microrheology and light transmission of blood. I. The photometric effects of red cell aggregation and red cell orientation | Q69096237 |
| | Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients | Q72595393 |
| | Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty | Q73727651 |
| | [Rapid physiological coagulation method in determination of fibrinogen] | Q74515389 |
| | Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) | Q74519754 |
| | THE AGGREGATION OF BLOOD PLATELETS | Q76530970 |
| | Hemorheological parameters in coronary artery disease | Q77313544 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| | aspirin | Q18216 |
| P304 | page(s) | 559-567 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Drugs & Aging | Q5308946 |
| P1476 | title | Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables | |
| P478 | volume | 23 | |